The FDA classification system for medical devices — Class I, Class II, and Class III, ordered from lowest to highest regulatory scrutiny — does not directly dictate which adhesive a device manufacturer must use. But the class of a device determines the regulatory pathway to market, which in turn determines what evidence must exist before the device can be sold, which determines how completely the adhesive must be characterized before it appears in a finished device. Selecting an adhesive without understanding how the device class affects the evidence requirements leads either to documentation gaps that delay submission or to overinvestment in testing that the regulatory pathway does not require.
Class I: General Controls and Minimum Documentation Requirements
Class I devices are those for which general controls — labeling, manufacturing under a Quality System Regulation, and prohibition of adulteration — are sufficient to ensure safety and effectiveness. Most Class I devices are non-contacting, non-critical, or of the nature where the generic regulatory framework adequately addresses risk. Examples include elastic bandages, examination gloves (non-sterile), and many handheld tools and instruments that do not contact the patient.
For adhesive use in Class I devices, the regulatory requirements are the lowest of the three classes. The device manufacturer must operate under a quality system, document the adhesive material and its specifications in the device master record (DHR), and demonstrate that the materials used in the device do not cause harm. But the level of pre-market scrutiny is low — Class I 510(k)-exempt devices do not require FDA premarket review, and the manufacturer’s documentation obligations are primarily internal.
In practice, Class I device adhesive selection prioritizes performance and process requirements. Biocompatibility testing may be relevant if there is patient contact, but many Class I devices have no patient contact. The documentation requirement is: identify the adhesive, specify it, and demonstrate through whatever evidence is appropriate (supplier data, literature, prior use history) that it does not cause harm in the intended use.
Medical-grade adhesives with available biocompatibility data are still preferred for Class I devices with patient contact — the documentation is easier when the data already exists than when the manufacturer must generate it. But the level of biocompatibility testing required is determined by the device’s patient contact, not by its FDA class per se.
Class II: Special Controls and 510(k) Pathway
Class II devices require special controls in addition to general controls to provide reasonable assurance of safety and effectiveness. Special controls may include performance standards, guidance documents, post-market surveillance, and specific labeling requirements. Class II devices go to market primarily through the 510(k) premarket notification pathway, which requires demonstrating substantial equivalence to a legally marketed predicate device.
The 510(k) submission for a Class II device must include a comparison of the new device to the predicate device, demonstrating equivalent intended use and equivalent or superior safety and effectiveness. For devices with patient contact, this comparison includes materials of construction — including adhesives. If the predicate device used a documented biocompatible adhesive and the new device uses the same adhesive at the same contact conditions, the materials comparison supports substantial equivalence.
If the new device uses a different adhesive than the predicate, or if no adequate predicate material comparison exists, the 510(k) must include a biological evaluation demonstrating that the new adhesive is biocompatible for the device’s contact conditions. The standard for this evaluation is ISO 10993, with the applicable test battery determined by the contact category and duration.
For Class II devices with indirect or surface patient contact — monitors, diagnostic instruments, powered surgical tools — the biocompatibility requirement is typically cytotoxicity, sensitization, and irritation (for skin contact or mucous membrane contact), plus extractables assessment if there is a fluid-contact pathway. A well-documented medical-grade epoxy with ISO 10993 test data satisfies this requirement without additional manufacturer-commissioned testing.
For specific biocompatibility documentation formatted for 510(k) submissions, Email Us — Incure can provide test reports and material summaries in FDA submission-compatible format.
Class III: PMA and Maximum Scrutiny
Class III devices are those that present the highest risk to patient safety and effectiveness, and include life-sustaining devices — pacemakers, ventricular assist devices, cochlear implants, and implantable drug delivery systems — as well as devices for which insufficient information exists to classify as Class II with special controls. Class III devices go to market through the Premarket Approval (PMA) pathway, which requires demonstration of safety and effectiveness through valid scientific evidence, including clinical data.
The PMA review is more rigorous than the 510(k) review, and the materials documentation required is correspondingly complete. For a permanently implantable Class III device, the biological evaluation must cover the full permanent implant contact endpoint matrix from ISO 10993-1: cytotoxicity, sensitization, irritation, systemic toxicity (subchronic and chronic), genotoxicity, implantation, hemocompatibility (if blood-contacting), and carcinogenicity and reproductive toxicity assessment for materials with significant patient exposure.
Adhesives in Class III implantable devices — bonding components inside hermetically sealed packages, potting lead/cable transitions, or any other structural role — must be characterized against this full endpoint matrix, even if the adhesive itself is inside a hermetic enclosure that prevents direct patient contact. The hermetic seal must be demonstrated to prevent migration of adhesive chemistry to the patient-contact surfaces, and the evidence for this is part of the PMA submission.
The documentation burden for Class III adhesive selection justifies choosing materials with the most complete existing biocompatibility data available — materials that have been previously used and documented in cleared or approved devices, or materials from suppliers who maintain a current permanent-implant biocompatibility data package.
The Common Thread Across All Classes
Regardless of device class, the principle is the same: the adhesive in a medical device must be demonstrated to be safe for the intended use. The level of demonstration required scales with the risk that patient harm would result from a failure — low-risk Class I devices require less evidence than high-risk Class III implants. Selecting an adhesive with an existing, well-documented biocompatibility data package reduces the manufacturer’s burden across all device classes, and for Class III applications, using materials with prior implant use history is the most efficient path through a demanding regulatory process.
Contact Our Team to discuss medical-grade epoxy selection, biocompatibility documentation, and regulatory submission support for Class I, II, and III medical device applications.
Visit www.incurelab.com for more information.